Lactylation-driven metabolic reprogramming acts as a central driver of therapeutic resistance in cancer, according to recent findings published in the journal Genes & Diseases by researchers Wanghao Zhang, Guanglong Huang, Woheng Tang, Jiaxian Li, Jingxian Chen, Yaojiang Feng, Kaichen Li, Can Pan, Shunshen Li, Huayang Zhang, Rongxu Ye, Hao Long, and Guo-zhong Yi. This cellular … Read more
Researchers at VCU Massey Comprehensive Cancer Center have developed an experimental molecule called an autophagy-targeting chimera (AUTAC) that dismantles the MCL1 survival protein to kill multiple myeloma cells. According to a study published in Cell Death & Disease, this targeted protein degrader works with existing proteasome inhibitors to reduce cancer cell viability by 50% within … Read more
Researchers at the Medical University of Vienna have discovered that the epidermal growth factor receptor (EGFR) influences immune cells within the tumor microenvironment of metastatic colorectal cancer, rather than acting solely on cancer cells. Published in Cell Death & Differentiation, the study suggests that silencing EGFR in myeloid cells—specifically macrophages—slows tumor growth and boosts the … Read more
Researchers at the Texas A&M Health Institute of Biosciences and Technology have developed a molecular switch called CODS (caffeine-operated dissociation system) that uses caffeine to control engineered cells. Published in the Journal of the American Chemical Society in 2026, the system allows scientists to trigger or pause gene-editing activity and immune cell responses on demand. … Read more